Clinical Trials
4 trialsNCT05431270 2026-05-19
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT02799862 2021-10-06
NEPTUN
iOMEDICO AG
Completed